Novel sulfonylurea and non-sulfonylurea drugs to promote the secretion of insulin

Trends in Endocrinology and Metabolism

Volumn 11, Issue 6, 2000, Pages 218-223

  Perfetti, Riccardo ^a   Ahmad, Azmi ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,1 DIMETHYL 2 (2 MORPHOLINOPHENYL)GUANIDINE FUMARATE; 2 (2 IMIDAZOLIN 2 Y1) 1 PHENYL 1H INDOLE; 4 HYDROXYISOLEUCINE; ACETOHEXAMIDE; AMINO ACID DERIVATIVE; CHLORPROPAMIDE; GLIBENCLAMIDE; GLIMEPIRIDE; GLIQUIDONE; INSULIN; MEGLITINIDE; MITIGLINIDE; NATEGLINIDE; PANCREAS TONIC; REPAGLINIDE; S3075; SULFONYLUREA; TOLAZAMIDE; TOLBUTAMIDE; UNCLASSIFIED DRUG;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CULTIVAR; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; HORMONE ACTION; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; LIGAND BINDING; LIVER CLEARANCE; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; STIMULATION, CHEMICAL; SULFONYLUREA COMPOUNDS;

EID: 0033867833     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-2760(00)00269-1     Document Type: Article

References (54)

1. LeRoith D.et al. Diabetes Mellitus. 1996;Lippincott-Raven.
2. Anonymous (1998) The worldwide burden of diabetes. Diabetes Care 21 (Suppl. 3), C1-C52.
3. + channels and insulin secretion: their role in health and disease. Diabetologia. 42:1999;903-919.
4. Goldberg R.B.et al. Dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The glimepiride protocol: 201 study group. Diabetes Care. 19:1996;849-856.
5. Bloomgarden Z.T. New and traditional treatment of glycemia in NIDDM. Diabetes Care. 19:1995;295-299.
6. Schade D.S.et al. A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful. J. Clin. Pharmacol. 38:1998;636-641.
7. Deleers M., Malaisse W.J. Binding of hypoglycemic sulfonylureas to an artificial phospholipid bilayer. Diabetologia. 26:1984;55-59.
8. Leclercq-Meyer V., Malaisse W.J. Modulation of gliquidone action by forskolin in the pancreas of normal and GK rats. Am. J. Physiol. 273:1997;E52-E58.
9. Courtois P.et al. Pharmacokinetics of gliquidone, glibenclamide, gliclazide and glipizide in middle-aged and aged subjects. Res. Commun. Mol. Pathol. Pharmacol. 103:1999;211-222.
10. Harrower A.D. Pharmacokinetics of oral antihyperglycemic agents in patients with renal insufficiency. Clin. Pharmacokinet. 31:1996;111-119.
11. Borthwick L.J., Wilson S. Diabetic control with gliquidone - a short acting sulphonylurea. Eur. J. Clin. Pharmacol. 26:1984;475-479.
12. Harrower A.D. Comparison of efficacy, secondary failure rate, and complications of sulfonylureas. J. Diabetes Complications. 8:1994;201-203.
13. Malaisse W.J. Stimulation of insulin release by non-sulfonylurea hypoglycemic agents: the meglitinide family. Horm. Metab. Res. 27:1995;263-266.
14. Wolffenbuttel B.H.R., Graal M.B. New treatments for patients with type 2 diabetes mellitus. Postgrad. Med. J. 72:1996;657-662.
15. Bakkali N.A.et al. Effects of the methyl esters of pyruvate, succinate and glutamate on the secretory response tomeglitinide analogues in rat pancreatic islets. Pharmacol. Res. 33:1996;191-194.
16. Fuhlendorrf J.et al. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes. 47:1998;345-351.
17. Vinambres C.et al. Repaglinide preserves nutrient-stimulated biosynthetic activity in rat pancreatic islets. Pharmacol. Res. 34:1996;83-85.
18. 14C-repaglinide during non-labeled repaglinide multiple dosing. Clin. Pharmacol. Ther. 65:1999;187. (abstr.).
19. Kikuchi M. Modulation of insulin secretion in non-insulin dependent diabetes mellitus by two novel oral hypoglycemic agents, NN623 and A4166. Diabet. Med. 13:1996;S151-S155.
20. Wolffenbuttel B.H.R., Landgraf R. A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Diabetes Care. 22:1999;463-467.
21. Marbury T.et al. Repaglinide versus glyburide: a one-year comparison trial. Diabetes Res. Clin. Pract. 43:1999;155-166.
22. Moses R.et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 22:1999;119-124.
23. Hatorp V., Haug-Pihale G. Repaglinide pharmacokinetics in healthy and chronic liver disease subjects. Clin. Pharmacol. Ther. 65:1999;187. (abstr.).
24. Schwartz S.L.et al. Repaglinide in type 2 diabetes: a randomized double blind, placebo-controlled, dose-response study. Diabetes. 47:1998;98A. (abstr.).
25. Damsbo P.et al. A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients. Diabetes Care. 22:1999;789-794.
26. Lins L.et al. Pharmacology of the hypoglycemic sulfonylurea gliquidone; III. Conformational analysis. Pharmacol. Res. 34:1996;9-10.
27. Jijakli H.et al. Dissociation between the potency and reversibility of the insulinotropic action of two meglitinide analogues. Pharmacol. Res. 34:1996;105-108.
28. Malaisse W.J. Mechanism of action of a new class of insulin secretagogues. Exp. Clin. Endocrinol. Diabetes. 4:1999;S140-S143.
29. Nakashima E.et al. Effect of a novel hypoglycemic agent, KAD-1229 on glucose metabolism and fructose-2, 6-biphosphate content in isolated hepatocytes of normal rats. Diabetes Res. Clin. Pract. 34:1996;13-22.
30. Ohnota H.et al. Novel rapid- and short-acting hypoglycemic agent, a calcium (2s)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl) propionate (KAD-1229) that acts on the sulfonylurea receptor: comparison of effects between KAD-1229 and gliclazide. J. Pharmacol. Exp. Ther. 269:1994;489-495.
31. Rabuazzo A.M.et al. Glyburide and tolbutamide induce desensitization of insulin release in rat pancreatic islets by different mechanisms. Endocrinology. 131:1992;1815-1820.
32. Davalli A.M.et al. Human islets chronically exposed in vitro to different stimuli become unresponsive to the same stimuli acutely: evidence supporting specific desensitization rather than beta-cell exhaustion. J. Clin. Endocrinol. Metab. 74:1992;790-794.
33. Sauvaire Y.et al. 4-Hydroxyisoleucine: a novel amino acid potentiator of insulin secretion. Diabetes. 47:1998;206-210.
34. Trecroci D. Pancreas Tonic looks for credibility from mainstream diabetes community. Diabetes Interview. 9:2000;21-29.
35. Broca C.et al. 4-Hydroxyisoleucine: experimental evidence of its insulinotropic and antidiabetic properties. Am. J. Physiol. 277:1999;E617-E623.
36. Genet S.et al. Effects of vanadate, insulin and fenugreek (Trigonella foenum graecum) on creatine kinase levels in tissues of diabetic rat. Indian J. Exp. Biol. 37:1999;200-202.
37. Akiyoshi M.et al. A new hypoglycemic agent, A-4166, inhibits ATP-sensitive potassium channels in rat pancreatic beta cells. Am. J. Physiol. 268:1995;E185-E193.
38. Ikenoue T.et al. Effect of a new hypoglycemic agent, A4166 [(-)-N (trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine], on postprandial blood glucose excursion: comparison with voglibose and glibenclamide. Biol. Pharm. Bull. 20:1997;354-359.
39. Ikenoue T.et al. Hypoglycemic and insulinotropic effects of a novel oral antidiabetic agent, (-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine (A-4166). Br. J. Pharmacol. 120:1997;137-145.
40. Sato Y.et al. Possibility of ideal blood glucose control by a new oral hypoglycemic agent, N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166), and its stimulatory effect on insulin secretion in animals. Diabetes Res. Clin. Pract. 12:1991;53-59.
41. Dunning B.E., Gutierrez C. Pharmacodynamics of nateglinide and repaglinide in Cynomolgus monkeys. Diabetes. 48:1999;104A. (abstr.).
42. Kalabag J.et al. Comparison of mealtime glucose regulation by nateglinide in healthy subjects. Diabetes. 48:1999;106A. (abstr.).
43. Bloomgarden Z.T. New and traditional treatment of glycemia in NIDDM. Diabetes Care. 19:1996;295-299.
44. Hirschberg Y.et al. Pharmacodynamics and dose response of nateglinide in type 2 diabetics. Diabetes. 48:1999;100A. (abstr.).
45. Storey D.A., Bailey C.J. Biphasic insulin-releasing effect of BTS 67,582 in rats. J. Pharm. Pharmacol. 50:1998;1357-1360.
46. Page T., Bailey C.J. Glucose-lowering effect of BTS 67,582. Br. J. Pharmacol. 122:1997;1464-1468.
47. Dickinson K.et al. BTS 67,582 stimulates insulin secretion from perifused rat pancreatic islets. Eur. J. Pharmacol. 339:1997;69-76.
48. Jones R.B.et al. Evaluation of BTS 67,582, a novel antidiabetic agent, in normal and diabetic rats. Br. J. Pharmacol. 120:1997;1135-1143.
49. McClenaghan N.H.et al. Insulin-releasing action of the novel antidiabetic agent BTS 67,582. Br. J. Pharmacol. 123:1998;400-404.
50. Louchami K.et al. Effect of 1,1-dimethyl-2-[2-morpholinophenyl] guanidine fumarate on pancreatic islet function. Eur. J. Pharmacol. 352:1998;289-297.
51. Skillman C.A., Raskin P. A double-masked placebo-controlled trial assessing effects of various doses of BTS 67,582, a novel insulinotropic agent, on fasting hyperglycemia in NIDDM patients. Diabetes Care. 20:1997;591-596.
52. +-ATP channels and interaction with exocytotic machinery. Diabetes. 45:1996;1610-1618.
53. 2+ mobilization from thapsigargin- sensitive stores in mouse pancreatic β cells. Diabetes. 47:1998;211-218.
54. 2+ from endoplasmic reticulum, and interaction with exocytotic machinery. Ann. New York Acad. Sci. 881:1999;241-252.